Amgen Inc
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Total Product Sales — U.S. volume growth YoY by Year
Total Product Sales — U.S. volume growth YoY (%) (%)
Amgen Total Product Sales — U.S. volume growth YoY: 13.0% in FY2025, down 13.0 pts from a year earlier.
Latest, FY2025
13.0%
Period ended Dec 31, 2025
Change on a year earlier
-13.0 pts
26.0% in FY2024
History
2 years
Since FY2024
Sources
2
Documents cited below
Where the FY2025 figure comes from
“U.S. volume grew 13% and ROW volume grew 14%, driven by volume growth in certain brands, including Repatha, PAVBLU, EVENITY, IMDELLTRA/IMDYLLTRA and TEZSPIRE.”
Source: Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K Item 2/7 MD&A Product Sales Overview.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total Product Sales — U.S. volume growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 13.0% | -13.0 pts | Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 26.0% | – | Form 10-K (amgn-20241231.htm, filed 2025-02-14) ↗ |
Cite this data
StockData. (2026). Amgen Total Product Sales — U.S. volume growth YoY (%), annual FY2024–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-total-us-vol
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.